Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.60 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2472969 | 0.98 | MEN1 (0.63) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL11641054 | 0.88 | KMT2A (0.56) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL5141417 | 0.87 | MEN1 (0.71) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL11644163 | 0.86 | ALDH1A1 (0.59) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL11647290 | 0.85 | CA1 (0.68) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL19747848 | 0.85 | CA1 (0.67) | MEN1KMT2AMAPTLMNACA1 | |
| SCHEMBL18530322 | 0.84 | MEN1 (0.68) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL9428788 | 0.84 | MAPT (0.62) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL11692400 | 0.84 | KMT2A (0.49) | MEN1KMT2AMAPTALDH1A1HSD17B10 | |
| SCHEMBL7646371 | 0.84 | MEN1 (0.67) | MEN1KMT2AMAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224255-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | claimed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | claimed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3224255-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | claimed |
| WO-2016083818-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | claimed |
| EP-3224255-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3224255-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016083818-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1581222-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6949658-B2 | Process for producing optically active α-amino acid and optically active α-amino acid amide | MITSUBISHI RAYON CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | MITSUBISHI RAYON CO., LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1300392-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171597-A1 | Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine | AADAT, BCAT1, BCAT2 | MEN1 3310/4885KMT2A 902/4885MAPT 2757/4885 |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | MEN1 816/4885KMT2A 389/4885MAPT 4519/4885 |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | MEN1 1961/4885KMT2A 4237/4885MAPT 3300/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | MEN1 816/4885KMT2A 389/4885MAPT 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.